Astrazeneca (AZN) Net Cash Flow (2009 - 2026)

Astrazeneca has reported Net Cash Flow for 18 years, with the latest figure at -$94.0 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 103.68% year-over-year to -$94.0 million in Q2 2026; TTM through Jun 2026 was $11.1 billion, a 24.33% decrease from a year earlier, with the FY2025 full-year figure at $15.5 billion, up 100.13% from the prior year.
• Net Cash Flow was -$94.0 million for Q2 2026 at Astrazeneca, down from $3.1 billion in the prior quarter.
• The five-year high for Net Cash Flow was $12.9 billion in Q4 2023, with the low at -$94.0 million in Q2 2026.
• Average Net Cash Flow over 5 years is $4.0 billion, with a median of $3.3 billion recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 3269.86% in 2025, then tumbled 103.68% in 2026.
• Over 5 years, Net Cash Flow stood at $12.1 billion in 2022, then rose by 6.89% to $12.9 billion in 2023, then plunged by 73.33% to $3.5 billion in 2024, then slumped by 48.09% to $1.8 billion in 2025, then sank by 105.25% to -$94.0 million in 2026.
• The last three Net Cash Flow figures came in at -$94.0 million (Q2 2026), $3.1 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.